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Abstract: 
Leprosy is an infectious disease caused by Mycobacterium leprae. M. leprae has undergone a major reductive evolution leaving a minimal 
set of functional genes for survival. It remains non-cultivable. As M. leprae develops resistance against most of the drugs, novel drug targets 
are required in order to design new drugs. As most of the essential genes mediate several biosynthetic and metabolic pathways, the pathway 
predictions can predict essential genes. We used comparative genome analysis of metabolic enzymes in M. leprae and H. sapiens using 
KEGG pathway database and identified 179 non-homologues enzymes. On further comparison of these 179 non-homologous enzymes to the 
list of minimal set of 48 essential genes required for cell-wall biosynthesis of M. leprae reveals eight common enzymes. Interestingly, six of 
these eight common enzymes map to that of peptidoglycan biosynthesis and they all belong to Mur enzymes. The machinery for 
peptidoglycan biosynthesis is a rich source of crucial targets for antibacterial chemotherapy and thus targeting these enzymes is a step 
towards facilitating the search for new antibiotics. 
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Background: 
The availability of the complete genome sequences of several 
pathogenic bacteria and the completion of the human genome 
project has revolutionized the field of drug-discovery against 
threatening human pathogens [1]. Novel drug targets are required in 
order to design new drugs against antibiotic sensitive pathogens. In 
general, a target should provide adequate selectivity yielding a drug 
which is specific or highly selective against the pathogen with 
respect to the human host. Moreover, the target should be essential 
for growth and viability of the pathogen at least under the condition 
of infection [2]. The search for potential drug targets has 
increasingly relied on genomic approaches. The entire approach is 
built on the assumption that the potential target must play an 
essential role in the pathogen's survival and constitute a critical 
component in its metabolic pathway. At the same time, this target 
should not have any well-conserved homolog in the human host. 
This would preclude the possibilities of unacceptable cross-
reactivity that might prove detrimental to the host [3]. Leprosy is 
caused by Mycobacterium leprae, which primarily affects the skin, 
mucous membranes and peripheral nerves causing deformities. 
Leprosy remains a major global health problem, especially in the 
developing world. For over a century leprosy has presented major 
challenges in the fields of microbiology, pathology, immunology, 
and genetics; it continues to do so today. Computer analysis 
demonstrated that only half of the sequence contains protein-coding 
genes. The other half contains pseudo genes and non-coding 
sequences. These findings indicate that M. leprae has undergone a 
major reductive evolution leaving a minimal set of functional genes 
for survival [4]. Study of the coding region of the sequence provides 
evidence accounting for the particular pathogenic properties of M. 
leprae which is an obligate intracellular parasite. Mycobacterium 
leprae remains non-cultivable [5].  M. leprae had mutational 
changes in some of their genes like gyrA, rpoB, and folP which 
developed resistance against drugs like newer quinolones, 
refampicin and dapsone [6]. Resistant strains of M. leprae appeared 
due to mutations in the macrolide target, the ribosome [7]. These 
findings suggest the emergence of multi-drug resistant M. leprae. 
Hence the mycobacterial cell wall with its specific composition and 
structure is considered to be a major factor in promoting the natural 
resistance of mycobacteria to various antibiotics. Early detection of 
Mycobacterium leprae infection is considered an important 
component of strategies aiming at reducing transmission of 
infection, but currently available diagnostic tools often lack 
sufficient sensitivity and specificity to reach this goal [8]. In clinical 
studies, notable progress has been made concerning the 
immunology and immunopathology of leprosy, the genetics of 
human resistance, mechanisms of nerve injury, and chemotherapy. 
In nearly all of these areas, however, leprosy remains poorly 
understood compared to other major bacterial diseases [9]. Here, we 
present a computational approach to identify the genes essential to 
M. leprae using comparative pathway analysis followed by mapping 
of non-homologues genes with list of minimal set of essential genes 
required for cell-wall biosynthesis of M. leprae.  In addition, our 
approach successfully identified a unique group of common 
enzymes as promising protein targets for new antibiotic 
development and further characterization in the laboratory. 
 
Methodology:  
Collection of metabolic pathway enzymes of M. leprae  
Kyoto Encyclopedia of Genes and Genomes (KEGG) [10] is a 
collection of online databases dealing with genomes, enzymatic 
pathways, and biological chemicals. KEGG maintains five main 
databases. They are KEGG Atlas, KEGG Pathway, KEGG Genes, 
KEGG Ligand and KEGG BRITE.  First, we collected all the 
metabolic pathways of M. leprae and H. sapiens from KEGG 
pathway database. Each of the pathways of M. leprae was compared 
with all the available pathways of H. sapiens to identify whether 
that particular pathway of M. leprae is present in H. sapiens or not. 
The pathways which were present in both M. leprae and H. sapiens 
were separated out and were named as shared pathways. The 
pathways which were present only in M. leprae but were not present 
in  H. sapiens were grouped together and were called as unique 
pathways. The gene name and the enzyme commission number 
(EC) of all the enzymes present in both shared and unique pathways 
were identified and collected from KEGG Genes database. 
 
Retrieval of protein sequences and BLAST  
The protein sequence of all enzymes in both shared and unique 
pathways of m. leprae were retrieved from UNIPROT [11] in 
FASTA format. Each protein sequence was subjected to BLASTP 
analysis against the H. sapiens at an E-value cutoff of 10
-4 [12]. 
BLAST results with no hits with H. sapiens were identified as non-
homologues enzymes of M. lepare. 
 
Identification of essential Enzymes 
The minimal set of essential genes required for cell envelope 
biosynthesis of m. leprae was reported previously using 
comparative genome sequence method by Vissa and Brennan [13]. 
The M. leprae enzymes which were non homologous to H. sapiens 
were mapped with the gene list of Vissa & Brennan and the most 
common M. leprae genes were identified and further explored. 
 
Results and discussion: 
Metabolic pathway information  
In KEGG pathway database we found 99 metabolic pathways for M. 
leprae  and 210 metabolic pathways for H. sapiens. Out of 99 
metabolic pathways for M. leprae five pathways are unique to M. 
leprae alone and comprised of 29 enzymes and remaining 94 Bioinformation   open access 
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pathways are present in H. sapiens as well and comprised of 731 
enzymes. The five unique pathways of m. leprae, 29 enzymes 
specific to these pathways and their corresponding gene id and the 
EC number were represented Table 1 (see supplementary 
material).  
 
Prediction of enzymes which were non homologous to human 
Removing enzymes from the pathogen that share a similarity with 
the host protein ensures that the targets have nothing in common 
with the host proteins and thereby, eliminating undesired host 
protein-drug interactions. BLASTP similarity search of all these 760 
(29 unique + 731 shared) enzymes at an E-value cutoff of 10
-4 
resulted 179 non-homologues enzymes of m. leprae of which ten 
enzymes from the unique pathways and the remaining 169 belong to 
enzymes from shared pathways.  All these 179 enzymes with their 
corresponding gene-id and EC number were represented in Table 2 
(see supplementary material). 
 
Comparison of non-homologues enzymes with essential gene set  
The 179 (10 + 169) non-homologues enzymes were further 
compared to the minimal set of 48 essential genes required for cell-
wall biosynthesis of M. leprae and reported by Vissa and Brennan 
[13]. There are eight enzymes common in both data sets (Table 3 in 
supplementary material). Among the eight common enzymes only 
one enzyme was found to be present in unique pathway and the 
remaining seven enzymes were found to be present in shared 
pathways. All these eight enzymes were categorized as essential 
enzymes of m. leprae.  
 
Role of essential enzymes of M. leprae 
All the eight essential enzymes were further analyzed for the 
identification of potential drug targets. One of the eight essential 
enzymes Alanine racemase (alr) is the enzyme found in D-Alanine 
metabolism which is a unique pathway of M. leprae. It is also found 
in Alanine and Aspartate metabolism which is a shared pathway of 
M. leprae. Another essential enzyme Putative dTDP-4-
dehydrorhamnose 3, 5-epimerase (rmlC) was found to be essential 
for Nucleotide sugar metabolism which is a shared pathway of M. 
leprae. It was also found to be essential for polyketide sugar unit 
biosynthesis which is a unique pathway of M. leprae. The remaining 
6 essential enzymes murC, murD, murE, murF, murG and murY 
were found to be essential for Peptidoglycan biosynthesis. It is 
noteworthy that all these 6 enzymes belong to the same family. This 
particular pathway, peptidoglycan biosynthesis was analyzed for the 
prediction of drug targets. 
 
Peptidoglycan biosynthesis and Mur enzymes  
M. leprae posses a multilayered cell envelope which basically 
consisted of, from inner to outer layer, a plasma membrane (PM), a 
peptidoglycan layer (PG), an electron translucent layer (ETL), and 
an irregular electron dense outer layer (OL) [14]. This bacterial cell 
envelope provides strength and rigidity to counteract internal 
osmotic pressure, and protection against the environment. The 
peptidoglycan layer gives the cell wall its strength, and helps to 
maintain the overall shape of the cell. The basic peptidoglycan 
structure of both Gram-positive and Gram-negative bacteria is 
comprised of a sheet of glycan chains connected by short cross-
linking polypeptides. Biosynthesis of peptidoglycan is a multi-step 
process comprising three main stages: (1) Formation of UDP-N-
acetylmuramic acid (UDPMurNAc) from N-acetylglucosamine 
(GlcNAc). (2) Addition of a short polypeptide chain to the 
UDPMurNAc. (3) Addition of a second N-acetylglucosamine 
(GlcNAc) to the disaccharide-pentapeptide building block and 
transport of this unit through the cytoplasmic membrane and 
incorporation into the growing peptidoglycan layer.  
The second step of the petidoglycan biosynthesis was carried out by 
four of the mur ligase enzymes MurC, MurD, MurE and MurF. 
These four Mur ligases are responsible for the successive additions 
of L-alanine, D-glutamate, meso-diaminopimelate or L-lysine, and 
D-alanyl-D-alanine to UDP-N-acetylmuramic acid. The final step in 
the formation of peptidoglycan was carried out by murG enzyme 
(N-acetyl glucosaminyl transferase). This enzyme is peripherally 
associated with the inner face of the cytoplasmic membrane. 
Therefore, the peptidoglycan subunit is completely assembled 
before it traverses the cytoplasmic membrane. Phospho-N-
acetylmuramoyl-pentapeptide-transferase (mraY) is an important 
enzyme in murein synthesis. It is responsible for the formation of 
the first lipid intermediate of the cell wall peptidoglycan synthesis 
[15]. As the layer of the bacterial cell wall that confers strength is 
the peptidoglycan meshwork if we target murC, murD, murE and 
murF which catalyze the addition of a short polypeptide chain to the 
UDP-N-acetylmuramic acid (UDPMurNAc), we can easily prevent 
the synthesis of bacterial cell wall. Thus, these are excellent 
candidates for further exploration. 
 
Conclusion: 
The availability of full genome sequences and computer-aided 
analysis to identify probable antimicrobial drug targets has become 
a new trend in pharmacogenomics. The use of a comprehensive set 
of unique pathways and enzymes present in these pathways of M. 
leprae to identify new drug targets were documented in this study. 
We have found peptidoglycan biosynthetic pathway and the six mur 
enzymes (murC, murD, murE, murF, murG and murY) involved in 
this pathway to be used as potential drug targets. Protein structure 
and inhibitors of these important enzymes are not currently 
available. Further analysis on the structural studies on these mur 
enzymes is believed to provide valuable insights towards the design 
of an inhibitor specific to the peptidoglycan biosynthesis of M. 
leprae for the treatment of leprosy. The availability of the newer 
anti-leprotic drugs in the future would definitely support our present 
findings such that there would be a possibility of mur enzymes 
which were proposed by us for targeting M. leprae.  
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Table 1: The five unique pathways and 29 enzymes specific to these pathways of m. leprae 
S. No  Name of the Pathway  Enzyme  EC # 
1. D-Alanine metabolism 
1   D-Alanyl-alanine synthetase A  Ddl  6.3.2.4 
2 Alanine  racemase  Alr  5.1.1.1 
2. Ethylbenzene degradation 
3 Acetyl-CoA  acyltransferase  fadA 2.3.1.16 
4 Mycolytransferase  fbpA  2.3.1.- 
3. Benzoate degradation via CoA ligation 
5 Monooxygenase    1.14.13.- 
6  Hypothetical protein     2.7.1.- 
7 Amidase  amiE 3.5.1.4 
8 Antigen  85-A  fbpA  2.3.1.- 
9  Putative acyl-CoA synthetase  fadD32  6.2.1.- 
10 Enoyl-CoA  hydratase  echA1 4.2.1.17 
11 Acetyl-CoA  acetyltransferase  fadA4  2.3.1.9 
12  Succinate dehydrogenase iron-sulfur subunit  sdhB  1.3.99.1 
4. 1,1,1-Trichloro-2,2-bis(4-chlorophenyl)ethane (DDT) degradation 
13 Trans-acting  enoyl  reductase    1.3.1.- 
14 Putative  oxidoreductase    1.2.-.- 
5. Two component system 
15  Acetyl-CoA acetyltransferase  A to B  2.3.1.9 
16  cytochrome c oxidase subunit XV assembly protein (A)  CtaA    
17 Glutamine  synthetase  GlnA  6.3.1.2 
18  Putative two-component response regulator  MprA    
19  Putative two-component system sensor histidine kinase  MprB  2.7.13.3 
20  Putative two-component response regulator  MtrA    
21  Putative two-component system sensor histidine kinase  MtrB  2.7.13.3 
22  Putative serine protease  PepD  3.4.21.- 
23  Two-component response regulator  PrrA    
24  Sensor histidine kinase  PrrB  2.7.13.3 
25  Tryptophan synthase subunit alpha  TrpA  4.2.1.20 
26  Tryptophan synthase subunit beta  TrpB  4.2.1.20 
27 Indole-3-glycerol-phosphate  synthase  TrpC  4.1.1.48 
28  Anthranilate phosphoribosyl transferase  TrpD  2.4.2.18 
29  Anthranilate synthase component I  TrpE  4.1.3.27 
 
Table 2: The 179 non-homologous enzymes m. leprae 
Gene  EC #  Gene  EC #  Gene  EC #  Gene  EC #  Gene  EC # 
ppgK  2.7.1.63 Adi 4.1.1.19  murG  2.4.1.227      1.2.1.- SecA,azi,div     
glpX  3.1.3.11  murI  5.1.1.3  mraY  2.7.8.13     3.3.2.8  SecD    
Fba 4.1.2.13 panD 4.1.1.11 uppP 3.6.1.27      3.1.1.45  SecE     
Fba 1.1.1.42  Asd  1.2.1.11  thiE  2.5.1.3  rpoA    SecF     
rpiB 5.3.1.6  thrB  2.7.1.39 thiL 2.7.4.16 Omega 2.7.7.6  SecG     
otsA  2.4.1.15  Ask  2.7.2.4  ThiC     rplO    SPase I  3.4.21.89 
otsB2 3.1.3.12  sdaA  4.3.1.17  ThiG      rplR    SPase  II  3.4.23.36 
    3.2.1.21 metE 2.1.1.14 ribG  1.1.1.193 rpiU    TatA     
murA  2.5.1.7  ilvC  1.1.1.86 cobT 2.4.2.21  rplV    TatB     
murB 1.1.1.158  ilvD  4.2.1.9  ribC  2.5.1.9  rplY    TatC     
rmlC 5.1.3.13  Hom  1.1.1.3  ribA  3.5.4.25  rpmC    YajC     
glcB 2.3.3.9  dapD 2.3.1.117 ribG 3.5.4.26  rpmD    YidC     
ppdK  2.7.9.1  dapF  5.1.1.7  RIBB     rpmG    dnaE – α subunit  2.7.7.7 
Ppc 4.1.1.31  murF  6.3.2.10 YaaD  4.-.-.-  rpmE    dnaN  –  β subunit  2.7.7.7 
gltB 1.4.1.13  murE  6.3.2.13 YaaE  2.6.-.-  rpmF    Subunit  –  δ 2.7.7.7 
cynT 4.2.1.1  hisD  1.1.1.23 nadD 2.7.7.18  rpmH    DnaB  3.6.1.- 
cysE  2.3.1.30  hisG  2.4.2.17  nadA     rpmI     DnaG  2.7.7.- 
metX 2.3.1.31  hisI  3.5.4.19 COAX 2.7.1.33  rpmJ      rnhB  3.1.26.4 
Dxr 1.1.1.267  hisE  3.6.1.31  acpS  2.7.8.7  Rrs    ssb   
pgsA 2.7.8.5  hisB  4.2.1.19 panC  6.3.2.1  Rrf    Nfo  3.1.21.2 
pssA 2.7.8.8  hisA  5.3.1.16 panB 2.1.2.11  rpsC    Tag   
Cdh 3.6.1.26  HisF  4.1.3.-  bioB  2.8.1.6  rpsD      UVRC   
Psd 4.1.1.65  HisH  2.4.2.-  folB  4.1.2.25  rpsJ,nusE    xseA  3.1.11.6 
dnaN  2.7.7.7  aroE  1.1.1.25  Folk  2.7.6.3  rpsN     Dpo III  2.7.7.7 
Dgt 3.1.5.1  ML2472  1.3.1.12 folP 2.5.1.15  rpsO      PriA  3.6.1.- 
thyX 2.1.1.148  trpD  2.4.2.18  hemD 2.1.1.107  rpsQ    RecF   
Cmk  2.7.4.14 aroA 2.5.1.19  hemD  4.2.1.75  rpsT    RecO   
pyrH  2.7.4.22 aroG 2.5.1.54  COX15      OppB      RecR   
pyrF  4.1.1.23 aroD 4.2.1.10  MENC  4.2.1.113  OppC      RuvA   
murC 6.3.2.8  pheA  4.2.1.51 MenD 2.5.1.64  ProX      RuvC  3.1.22.4 
murD 6.3.2.9  aroB  4.2.3.4  argC  1.2.1.38  PstA      argB  2.7.2.8 Bioinformation   open access 
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CbiQ     hisA  5.3.1.24  argJ  2.3.1.1  pstC     MenD  4.1.1.71 
FhuC   3.6.3.34  OppA     argJ  2.3.1.35  RfbA     YrbD    
FhuD     FtsX    YrbE     YadH     PrrA***    
 ddl  6.3.2.4  prrB  2.7.13.3  ctaA     trpC  4.1.1.48     2.7.1.- 
 




Table 3: Essential enzymes of M. leprae  
S. No  Enzyme  
name 
Name of the Enzyme  Name of the pathway 
D-Glutamine & D-Glutamate 
metabolism. 
1  murC  UDP-N-acetylmuramate—L-alanine ligase 
Peptidoglycan biosynthesis 
D-Glutamine & D-Glutamate 
metabolism. 
2  murD  UDP-N-acetylmuramoyl-L-alanyl-D-glutamate synthetase 
Peptidoglycan biosynthesis 
Peptidoglycan biosynthesis  3  murE  UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate 
ligase Lysine  biosynthesis 
Peptidoglycan biosynthesis  4  murF  UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate--D-
alanyl-D-alanyl ligase (D-alanine:D-alanine-adding enzyme)                       Lysine biosynthesis 
5  murG  N-acetylglucosaminyl transferase  Peptidoglycan biosynthesis 
6  mraY  Phospho-N-acetylmuramoyl-pentapeptide-transferase Peptidoglycan  biosynthesis 
Nucleotide sugars metabolism.  7  rmlC  Putative dTDP-4-dehydrorhamnose 3,5-epimerase 
Polyketide sugar unit biosynthesis 
D-Alanine metabolism.   8  alr  Alanine racemase 
Alanine & Aspartate metabolism 
 
 
                        